title: Current status of publicly available sarcoma cell lines for use in proteomic studies.
abstract: Cell lines are valuable resources for proteomic studies and can be used as tools to verify the significance of proteomic findings. Here, the authors overview the current status of the publicly available sarcoma cell lines. The authors surveyed seven major cell banks and found that the diversity observed in the sarcoma cell banks was largely insufficient; sarcoma cell lines are available for only a limited histological subtype. They also observed a number of issues with the pathological diagnosis of the cell lines, limitations in their behavioral diversity, and various unmet needs. Well characterized cell lines with accurate diagnosis based on modern diagnosis criteria should be available from public cell banks. The authors conclude that additional cell lines, along with detailed genetic and pathological analyses, should be prepared and deposited in order to promote sarcoma-specific proteomic research. The authors focused on sarcoma cell lines, but their discussion can be applied to the other cancers.
authors.affiliation: a Division of Rare Cancer Research , National Cancer Center Research Institute , Tokyo , Japan.
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Pan
authors.affiliation: b Department of Pathology , National Cancer Center Hospital , Tokyo , Japan.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshida
authors.affiliation: c Division of Musculoskeletal Oncology , National Cancer Center Hospital , Tokyo , Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Kawai
authors.affiliation: a Division of Rare Cancer Research , National Cancer Center Research Institute , Tokyo , Japan.
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kondo
mesh_terms: D045744:Cell Line, Tumor; D006801:Humans; D040901:Proteomics; D012509:Sarcoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology*
keywords: Sarcoma; biomarker; cell bank; cell line; proteomics; therapeutic target